Mature myeloid cells fail to fully recover after deletion of both Mpc2 and Gls. (A) Peripheral blood CD45.2 chimerism of mature cells was assessed every 2 wk. Values are normalized to pre-tamoxifen chimerism of each cell type. Each line represents longitudinal analysis of individual mice with a symbol at each time point measured. Data are pooled from two independent experiments. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by paired two-way ANOVA with post-hoc Tukey’s multiple comparisons test. (B) CD45.2 chimerism of bone marrow progenitors normalized to HSC chimerism immediately following 2 wk of tamoxifen administration. Each symbol represents an individual mouse. Mean values ± SEM are shown. Data are pooled from two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by two-way ANOVA with post-hoc Tukey’s multiple comparisons test. (C) BrdU incorporation was measured in both CD45.1⁺ (WT) and CD45.2⁺ (WT or recent deletion of Gls and Mpc2) CMPs, GMPs, and CMoPs following a 1-h pulse of BrdU. Each line connects CD45.1⁺ and CD45.2⁺ cells within the same mouse (n = 9 for WT chimeras and n = 6 for recent DKO chimeras). Mice in which Mpc2 was <90% reduced relative to WT controls were excluded. Data are pooled from two independent experiments. P values >0.05 by paired two-way ANOVA with post-hoc Sidak’s multiple comparisons test are not depicted.